By Duncan Ferris
Date: Friday 23 Aug 2019
LONDON (ShareCast) - (Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.
The AIM -listed company said the first patient was dosed on 12 August in China and said approximately 50 to 60 patients would be enrolled in the placebo-controlled Phase Ib clinical trial.
The trial is primarily investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-523.
The primary endpoint is the number of patients with any adverse event, while the secondary endpoints are maximum plasma concentration, area under the concentration-time curve in a selected time interval, and rate of clinical remission at week 8.
Preliminary results of the dose escalation stage in a Phase I study in China of use of the drug in patients with relapsed or refractory B-cell lymphomas were presented in 2018, while a now complete Phase I dose escalation study in Australia in healthy volunteers showed that HMPL-523 was generally well tolerated.
Hutchison China Meditech shares were up 1.35% at 339.00p at 1054 BST.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 320.00p |
Change Today | -4.00p |
% Change | -1.23 % |
52 Week High | 352.00p |
52 Week Low | 173.60p |
Volume | 9,563 |
Shares Issued | 871.26m |
Market Cap | £2,788.02m |
RiskGrade | 226 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
11:49 | 4,280 @ 320.00p |
11:48 | 2,867 @ 320.12p |
10:05 | 1,562 @ 320.12p |
10:04 | 1 @ 320.01p |
09:44 | 157 @ 320.40p |
You are here: research